Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient's cancer, which may influence choice of treatment based on cancer stage and type
SOURCE: Illumina
DESCRIPTION:
SAN DIEGO, May 18, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving the Western Pennsylvania area, today announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling (CGP) to enhance patient care.
The collaboration will assess the value of in-house testing for both tissue and blood samples, versus sending those samples externally, and whether this approach may benefit cancer patients and the broader healthcare system. The collaboration will also work to identify instances where blood-based testing is most beneficial, depending on cancer stages and types.
The initiative is part of AHN Cancer Institute's plan to help improve the cancer care pathway through its newly established AHN Clinical Genomics Laboratory in Pittsburgh. Looking at approximately 1,000 samples, the collaboration will compare solid tissue biopsies with less invasive blood samples to see if regular blood testing can provide additional information on the genetic changes within a patient's cancer, which may be relevant to the choice of treatment. If so, less-invasive CGP testing of blood samples could potentially complement tissue sampling, substantially increasing the number of patients who are able to have their tumors profiled and be part of clinical trials for cancer therapy selection.
"We know that cancer results from a disrupted genome, and knowing the genetic changes in a patient's cancer increasingly results in personalized, targeted therapy and improved outcomes," said Phil Febbo, MD, Chief Medical Officer at Illumina. "Partnering with AHN to help them perform testing within their system will further advance their institutional expertise in genomic cancer diagnosis, increase opportunities to match their patients with personalized therapy, and improve patient outcomes."
"As an organization that treats more than 10,000 cancer patients each year, being at the forefront of cancer genetic profiling is critically important to our mission of helping pioneer the next generation of targeted therapies that will provide more effective treatment for all types of cancers," said David Bartlett, MD, Chair, AHN Cancer Institute. "We believe our collaboration with Illumina will help bring us closer to that reality."
The project commenced in 2022 and is slated for one year, with the potential to expand this clinical research in the future. Samples for the study have been collected across AHN Cancer Institute's 24 affiliated oncology clinics.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:
Salli Schwartz
+1.858.291.6421
ir@illumina.com
Media:
Adi Raval
+1.202.629.8172
ILMN-PR@illumina.com
SOURCE Illumina, Inc.
KEYWORDS: NASDAQ: ILMN, illumina, Allegheny Health Network, comprehensive genomic profiling, AHN Cancer Institute, cancer research, Dr. Phillip G. Febbo
